NSE › Healthcare

Gujarat Themis Biosyn Limited (GUJTHEM)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹420.15+1.83%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

₹44 cr

Revenue YoY

+22.1%

Net profit

₹11 cr

Profit YoY

+22.1%

Net margin

25.3%

Key statistics

Market cap

₹5,501 cr

P/E

96.1

Forward P/E

0.0

P/B

19.45

Book value

₹26.41

EPS (TTM)

₹4.40

52-week high

₹479.00

52-week low

₹225.05

50-day MA

₹381.07

200-day MA

₹358.47

Beta

0.51

Shareholding

Promoters

60.27%

Institutions

0.99%

Recent filings & reports

Document	Date
Annual report FY2026 GUJARAT THEMIS BIOSYN LIMITED - FY26 SUMMARY HEADLINE NUMBERS • Total Income: Rs. 168.25 crores (up from Rs. 153.23 crores in FY25) • Revenue from O	2026-09-04
Q1 FY27 earnings call GUJARAT THEMIS BIOSYN LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue from operations Q1 FY27: INR 43.8 crores vs INR 35.9 crores in Q1 FY26 —	2026-08-14
Investor presentation · Q1 FY27 GUJARAT THEMIS BIOSYN LIMITED – Q1 FY2026-27 INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: Rs. 43.8 crores, up 22.1% YoY (vs. Rs. 35.9 crores	2026-08-07
Quarterly results · Q1 FY27 GUJARAT THEMIS BIOSYN LIMITED – Q1 FY 2026-27 SUMMARY HEADLINE NUMBERS • Total Income (Q1 FY26-27): INR 4,392.16 lakhs (standalone), down from INR 4	2026-08-07
Investor presentation · Q4 FY26 GUJARAT THEMIS BIOSYN LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 16,582.28 lakhs (up 10% from FY25's INR 15,079.99 lakhs) • EBI	2026-06-29
Quarterly results · Q4 FY26 DOCUMENT SUMMARY: GUJARAT THEMIS BIOSYN LIMITED HEADLINE NUMBERS • Document Date: 20th June, 2026 • Company: Gujarat Themis Biosyn Limited • Stock Sy	2026-06-25
Investor presentation	2026-05-25
Investor presentation	2026-05-22

Readable in the app.

Corporate actions

Action	Detail	Date
Dividend	₹0.67 / share ex-date Sep 4, 2025 · record Sep 5, 2025	2025-09-04

Deals & corporate news

Announcement	Date
Acquisition of Sanofi's Global Anti-TB and Anti-Infective Portfolio Gujarat Themis Biosyn Limited announced the acquisition of Sanofi's global anti-tuberculosis (anti-TB) and anti-infective drug portfolio on April 23, 2026. This is a significant strategic mo	2026-04-23
Capacity addition announced Gujarat Themis Biosyn Limited has informed the Exchange about Capacity addition	2025-10-18

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gujarat Themis Biosyn Limited — free to start.

Google Play App Store

Other Healthcare companies

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Lenskart Solutions Ltd Zydus Lifesciences Limited Cipla Limited Laurus Labs Limited Max Healthcare Institute Limited Aurobindo Pharma Limited Lupin Limited Dr. Reddy's Laboratories Limited

Data updated 2026-09-18.